Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210169 | 0.86 | TDP1 (0.68) | TDP1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL25033933 | 0.85 | APEX1 (0.62) | TDP1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25935487 | 0.84 | POLB (0.60) | TDP1KDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL3213693 | 0.81 | ALDH1A1 (0.58) | TDP1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL30063371 | 0.81 | ALDH1A1 (0.58) | TDP1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL8198934 | 0.79 | APEX1 (0.56) | TDP1KDM4ERECQLMCL1ALDH1A1 | |
| SCHEMBL2676181 | 0.79 | TDP1 (0.58) | TDP1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1520429 | 0.77 | TDP1 (0.72) | TDP1KDM4EALDH1A1KMT2AHSD17B10 | |
| SCHEMBL21408921 | 0.76 | HDAC1 (0.54) | HTTTDP1LMNAMAPTPOLB | |
| SCHEMBL30475496 | 0.76 | APEX1 (0.58) | TDP1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2655334-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | Eutropics Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL9 | HTT 715/4885TDP1 1989/4885KDM4E 1427/4885 |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL2L1 | HTT 835/4885TDP1 1089/4885KDM4E 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.